Telomerase Activity in Tumor and Remnant Liver As Predictor of Recurrence and Survival in Hepatocellular Carcinoma After Resection

Overview

Journal World J Surg

Publisher Wiley

Specialty General Surgery

Date 2007 Apr 13

PMID 17429564

Citations 3

Authors

Yan-Shen Shan

Yu-Hsiang Hsieh

Pin-Wen Lin

Affiliations

Soon will be listed here.

Abstract

Background And Aim: Results after curative liver resection in hepatocellular carcinoma are unsatisfactory with regard to high postoperative intrahepatic recurrence and liver failure. This study evaluates telomerase activity in liver with and without tumor as a predictor of recurrence and survival.

Materials And Methods: Liver tissue with and without tumor from 53 hepatocellular carcinoma patients receiving curative resection during the period of 1998-2000 was used for detecting telomerase activity by PCR-ELISA. Clinicopathological data were compared to identify predictors of recurrence and survival.

Results: Telomerase activity was detected in 98% of liver tissue with tumor and 70% liver tissue without. Telomerase activity in cancerous liver correlated significantly with HCV infection (P = 0.012) and cirrhotic change in liver parenchyma (P = 0.006). Telomerase activity in non-cancerous liver correlated with high serum AFP level (P = 0.002). The telomerase activity of liver tissue with and without tumor is significant higher in patients with recurrence than in those without recurrence, 413.7 +/- 100.5 versus 110.8 +/- 32.7, P = 0.006, and 34.7 +/- 14.2 versus 4.2 +/- 1.4, P = 0.039. Recurrence could be predicted by abnormally high tumor telomerase activity (P = 0.026) or by advanced TNM stage (P = 0.001). TNM stage or high serum ALT level could predict multinodular intrahepatic recurrence (P = 0.028 and P = 0.030). High serum AFP combined with high telomerase activity in liver without tumor had a significant ability to predict poor survival (OR: 11.19, CI: 1.95-64.12, P = 0.007).

Conclusion: Tumor telomerase is an independent predictor of recurrence. Simultaneous high remnant liver telomerase and high serum AFP is a strong negative predictor of survival.

Citing Articles

Hepatic resection for large hepatocellular carcinoma in the era of UCSF criteria.

Delis S, Bakoyiannis A, Tassopoulos N, Athanassiou K, Kechagias A, Kelekis D HPB (Oxford). 2010; 11(7):551-8.

PMID: 20495706 PMC: 2785949. DOI: 10.1111/j.1477-2574.2009.00084.x.

Human telomerase activity, telomerase and telomeric template expression in hepatic stem cells and in livers from fetal and postnatal donors.

Schmelzer E, Reid L Eur J Gastroenterol Hepatol. 2009; 21(10):1191-8.

PMID: 19240645 PMC: 2743773. DOI: 10.1097/MEG.0b013e32832973fc.

Hepatocellular carcinoma: defining the place of surgery in an era of organ shortage.

Bartlett A, Heaton N World J Gastroenterol. 2008; 14(28):4445-53.

PMID: 18680222 PMC: 2731269. DOI: 10.3748/wjg.14.4445.

References

Kishimoto K, Fujimoto J, Takeuchi M, Yamamoto H, Ueki T, Okamoto E . Telomerase activity in hepatocellular carcinoma and adjacent liver tissues. J Surg Oncol. 1998; 69(3):119-24. DOI: 10.1002/(sici)1096-9098(199811)69:3<119::aid-jso1>3.0.co;2-q. View

Dusheiko G, Hobbs K, Dick R, Burroughs A . Treatment of small hepatocellular carcinomas. Lancet. 1992; 340(8814):285-8. DOI: 10.1016/0140-6736(92)92367-o. View

Puebla-Mora A, Heras A, Cano-Valdez A, Dominguez-Malagon H . Human telomerase and alpha-methylacyl-coenzyme A racemase in prostatic carcinoma. A comparative immunohistochemical study. Ann Diagn Pathol. 2006; 10(4):205-8. DOI: 10.1016/j.anndiagpath.2005.09.021. View

Ohta K, Kanamaru T, Morita Y, Hayashi Y, Ito H, Yamamoto M . Telomerase activity in hepatocellular carcinoma as a predictor of postoperative recurrence. J Gastroenterol. 1998; 32(6):791-6. DOI: 10.1007/BF02936956. View

Blasco M, Gasser S, Lingner J . Telomeres and telomerase. Genes Dev. 1999; 13(18):2353-9. DOI: 10.1101/gad.13.18.2353. View

Park Y, Choi J, Byun B, Cho C, Kim H, Kim B . Telomerase is strongly activated in hepatocellular carcinoma but not in chronic hepatitis and cirrhosis. Exp Mol Med. 1999; 30(1):35-40. DOI: 10.1038/emm.1998.5. View

Ogami M, Ikura Y, Nishiguchi S, Kuroki T, Ueda M, Sakurai M . Quantitative analysis and in situ localization of human telomerase RNA in chronic liver disease and hepatocellular carcinoma. Lab Invest. 1999; 79(1):15-26. View

Kobayashi T, Kubota K, Takayama T, Makuuchi M . Telomerase activity as a predictive marker for recurrence of hepatocellular carcinoma after hepatectomy. Am J Surg. 2001; 181(3):284-8. DOI: 10.1016/s0002-9610(01)00566-9. View

Suda T, Isokawa O, Aoyagi Y, Nomoto M, Tsukada K, Shimizu T . Quantitation of telomerase activity in hepatocellular carcinoma: a possible aid for a prediction of recurrent diseases in the remnant liver. Hepatology. 1998; 27(2):402-6. DOI: 10.1002/hep.510270213. View

10.

Belghiti J, Panis Y, Farges O, Benhamou J, Fekete F . Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg. 1991; 214(2):114-7. PMC: 1358509. DOI: 10.1097/00000658-199108000-00004. View

11.

Homma S, Komita H, Sagawa Y, Ohno T, Toda G . Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12. Immunology. 2005; 115(4):451-61. PMC: 1782174. DOI: 10.1111/j.1365-2567.2005.02179.x. View

12.

Coleman W . Mechanisms of human hepatocarcinogenesis. Curr Mol Med. 2003; 3(6):573-88. DOI: 10.2174/1566524033479546. View

13.

Unitt E, Rushbrook S, Marshall A, Davies S, Gibbs P, Morris L . Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells. Hepatology. 2005; 41(4):722-30. DOI: 10.1002/hep.20644. View

14.

Reddel R . The role of senescence and immortalization in carcinogenesis. Carcinogenesis. 2000; 21(3):477-84. DOI: 10.1093/carcin/21.3.477. View

15.

Huang G, Lee H, Chen C, Chiou L, Lin Y, Lee C . Telomerase activity and telomere length in human hepatocellular carcinoma. Eur J Cancer. 1999; 34(12):1946-9. DOI: 10.1016/s0959-8049(98)00237-8. View

16.

Poon R, Fan S, Lo C, Liu C, Wong J . Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann Surg. 1999; 229(2):216-22. PMC: 1191634. DOI: 10.1097/00000658-199902000-00009. View

17.

Shay J, Bacchetti S . A survey of telomerase activity in human cancer. Eur J Cancer. 1997; 33(5):787-91. DOI: 10.1016/S0959-8049(97)00062-2. View

18.

Tatsuma T, Goto S, Kitano S, Lin Y, Lee C, Chen C . Telomerase activity in peripheral blood for diagnosis of hepatoma. J Gastroenterol Hepatol. 2000; 15(9):1064-70. DOI: 10.1046/j.1440-1746.2000.02293.x. View

19.

Sato Y, Yamamoto S, Oya H, Nakatsuka H, Kobayashi T, Takeishi T . Preoperative human-telomerase reverse transcriptase mRNA in peripheral blood and tumor recurrence in living-related liver transplantation for hepatocellular carcinoma. Hepatogastroenterology. 2005; 52(65):1325-8. View

20.

Miura N, Maeda Y, Kanbe T, Yazama H, Takeda Y, Sato R . Serum human telomerase reverse transcriptase messenger RNA as a novel tumor marker for hepatocellular carcinoma. Clin Cancer Res. 2005; 11(9):3205-9. DOI: 10.1158/1078-0432.CCR-04-1487. View